<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103426</url>
  </required_header>
  <id_info>
    <org_study_id>0113-CL-0004</org_study_id>
    <nct_id>NCT02103426</nct_id>
  </id_info>
  <brief_title>An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients</brief_title>
  <official_title>A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether ASP0113 (a CMV deoxyribonucleic acid [DNA]&#xD;
      vaccine) can be detected in plasma after intramuscular (IM) injections, and to determine&#xD;
      whether CMV-seropositive healthy volunteers, CMV-seronegative healthy volunteers,&#xD;
      CMV-seronegative dialysis patients mount an immune response to the CMV proteins produced by&#xD;
      the vaccine after repeated ASP0113 IM injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 is open-label with no randomization, and Part 2 is single-blind and randomized. The&#xD;
      purpose of Part 1 is to obtain pilot pharmacokinetic data so as to optimize pharmacokinetic&#xD;
      sample collection times in Part 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2013</start_date>
  <completion_date type="Actual">May 10, 2016</completion_date>
  <primary_completion_date type="Actual">May 10, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ASP0113 plasmids pharmacokinetics in plasma: AUC (Part 1 and Part 2)</measure>
    <time_frame>Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2)</time_frame>
    <description>Area under the curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ASP0113 plasmids pharmacokinetics in plasma: Cmax (Part 1 and Part 2)</measure>
    <time_frame>Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2</time_frame>
    <description>Maximum Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ASP0113 plasmids pharmacokinetics in plasma: Tmax (Part 1 and Part 2)</measure>
    <time_frame>Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2</time_frame>
    <description>Time to maximum concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ASP0113 plasmids pharmacokinetics in plasma: Apparent clearance (Part 1 and Part 2)</measure>
    <time_frame>Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ASP0113 plasmids pharmacokinetics in plasma: apparent volume of distribution (Part 1 and Part 2)</measure>
    <time_frame>Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ASP0113 plasmids pharmacokinetics in plasma: half-life (Part 1 and Part 2)</measure>
    <time_frame>Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pp65 protein in white blood cells (WBCs) using pp65 antigenemia assay (Part 1 and Part 2)</measure>
    <time_frame>Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 , 28 for Part 1; Day 1, 10, 14, weeks 5, 7, 9, 11, 25 and 27 for Part 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: Relative units/ml of anti-gB antibodies in serum as detected by enzyme-linked immunosorbent assay (ELISA) (Part 2)</measure>
    <time_frame>Day 1 and weeks 3, 5, 7, 9, 11, 25 and 27 (Part 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: Number of pp65-specific Interferon (IFN)-gamma producing T-cells in isolated peripheral blood mononuclear cells (PBMCs) upon pp65 peptide stimulation as assayed by flow cytometry with intracellular cytokine staining (ICS) (Part 2)</measure>
    <time_frame>Day 1 and weeks 3, 5, 7, 9, 11, 25 and 27 (Part 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: Amount of IFN-gamma produced by CMV peptide-stimulated T-cells in whole blood using the QuantiFERON T-cell CMV assay (Part 2)</measure>
    <time_frame>Day 1 and weeks 3, 5, 7, 9, 11, 25 and 27 (Part 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by clinical labs, vital signs, and adverse events including local and systemic reactogenicity</measure>
    <time_frame>Up to Day 28 (Part 1), Up to 7 months (Part 2)</time_frame>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Dialysis</condition>
  <condition>Healthy Subjects</condition>
  <condition>Cytomegalovirus Infection</condition>
  <arm_group>
    <arm_group_label>Part 1: ASP0113 CMV-seropositive healthy cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg single dose IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: ASP0113 CMV-seronegative healthy cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg single dose IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo CMV-seropositive healthy cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo CMV-seronegative healthy cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: ASP0113 CMV-seropositive healthy cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 IM injections of ASP0113</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: ASP0113 CMV-seronegative healthy cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 IM injections of ASP0113</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: ASP0113 CMV-seronegative dialysis cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 IM injections of ASP0113</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo CMV-seropositive healthy cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 placebo IM injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo CMV-seronegative healthy cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 placebo IM injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo CMV-seronegative dialysis cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 placebo IM injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP0113</intervention_name>
    <description>intramuscular injection</description>
    <arm_group_label>Part 1: ASP0113 CMV-seronegative healthy cohort</arm_group_label>
    <arm_group_label>Part 1: ASP0113 CMV-seropositive healthy cohort</arm_group_label>
    <arm_group_label>Part 2: ASP0113 CMV-seronegative dialysis cohort</arm_group_label>
    <arm_group_label>Part 2: ASP0113 CMV-seronegative healthy cohort</arm_group_label>
    <arm_group_label>Part 2: ASP0113 CMV-seropositive healthy cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intramuscular injection</description>
    <arm_group_label>Part 1: Placebo CMV-seronegative healthy cohort</arm_group_label>
    <arm_group_label>Part 1: Placebo CMV-seropositive healthy cohort</arm_group_label>
    <arm_group_label>Part 2: Placebo CMV-seronegative dialysis cohort</arm_group_label>
    <arm_group_label>Part 2: Placebo CMV-seronegative healthy cohort</arm_group_label>
    <arm_group_label>Part 2: Placebo CMV-seropositive healthy cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Main Inclusion for Healthy Subjects:&#xD;
&#xD;
          -  Body Mass Index (BMI) range of 18.5 - 35.0 kg/m2; weighs at least 50 kg at Screening.&#xD;
&#xD;
          -  Female subject must not be lactating and must not be breast feeding within 3 months&#xD;
             before Screening or during the study period and for 28 days after final injection.&#xD;
&#xD;
          -  Female subject must not donate ova starting at Screening and throughout the study&#xD;
             period and for 28 days after final injection.&#xD;
&#xD;
          -  Highly likely to comply with the protocol and complete the study.&#xD;
&#xD;
          -  Estimated creatinine clearance calculated using the Cockcroft-Gault equation of &gt; 80&#xD;
             mL/min/1.73m2 (normal renal function).&#xD;
&#xD;
        Inclusion Criteria for Dialysis Patients:&#xD;
&#xD;
          -  BMI range of 18.5 - 40.0 kg/m2; weighs at least 50 kg at Screening.&#xD;
&#xD;
          -  Female subject must not be lactating and must not be breast feeding within 3 months&#xD;
             before Screening or during the study period and for 30 days after final injection.&#xD;
&#xD;
          -  Female subject must not donate ova starting at Screening and throughout the study&#xD;
             period and for 28 days after final study drug administration.&#xD;
&#xD;
          -  Must have adequate venous access.&#xD;
&#xD;
          -  Highly likely to comply with the protocol and complete the study.&#xD;
&#xD;
          -  Must currently be receiving hemodialysis treatment and for a period of at least 6&#xD;
             months prior to Screening.&#xD;
&#xD;
          -  CMV-seronegative at Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Main Exclusion Healthy Subjects&#xD;
&#xD;
          -  Female subject is pregnant at Screening.&#xD;
&#xD;
          -  Any clinically significant history of allergic conditions (including drug allergies,&#xD;
             asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies).&#xD;
&#xD;
          -  Any history or evidence of any clinically significant cardiovascular,&#xD;
             gastrointestinal, endocrinologic, hematologic, hepatic, metabolic, urologic,&#xD;
             pulmonary, neurologic, dermatologic, psychiatric, renal (for healthy subjects only)&#xD;
             and/or other major disease or malignancy (except non-metastatic basal or squamous cell&#xD;
             carcinoma of the skin that has been treated successfully or cancer in situ of the&#xD;
             cervix uteri that has been handled by local surgery).&#xD;
&#xD;
          -  History or evidence of autoimmune diseases including systemic lupus erythematosus,&#xD;
             rheumatoid arthritis, scleroderma, psoriasis, psoriatic arthritis and inflammatory&#xD;
             bowel disease.&#xD;
&#xD;
          -  Febrile illness or symptomatic, viral, bacterial (including upper respiratory&#xD;
             infection) or fungal (non-cutaneous) infection within 1 week prior to day -14.&#xD;
&#xD;
          -  Any of the liver function tests (LFT) (aspartate amino-transferase [AST] or alanine&#xD;
             aminotransferase [ALT] alkaline phosphatase (ALP), gamma-glutamyl transferase [GGT],&#xD;
             total bilirubin [TBil]) outside of normal limits at Screening.&#xD;
&#xD;
          -  Mean pulse &lt; 40 or &gt; 90 beats per minute (bpm), mean systolic blood pressure (SBP) &gt;&#xD;
             160 mmHg or mean diastolic blood pressure (DBP) &gt; 90 mmHg taken in triplicate after&#xD;
             the subject has been resting in a sitting position for at least 5 minutes at&#xD;
             Screening.&#xD;
&#xD;
          -  Positive serology test for hepatitis B surface antigen (HBsAg) or hepatitis core&#xD;
             immunoglobulin M (HBc [IgM]) antibody, anti-hepatitis A virus (HAV) IgM or anti-human&#xD;
             immunodeficiency virus type 1 and type 2 (HIV-1 and HIV-2) at Screening.&#xD;
&#xD;
          -  Positive serology test for anti-hepatitis C virus (HCV) and a confirmatory positive&#xD;
             reflex viral load test at Screening.&#xD;
&#xD;
          -  Current/ active CMV infection as evidenced by positive CMV Polymerase chain reaction&#xD;
             (PCR) plasma results at Screening.&#xD;
&#xD;
          -  Any known or suspected hypersensitivity to ASP0113 or any components of the&#xD;
             formulation used, including aminoglycosides as kanamycin is used during the&#xD;
             manufacturing of the vaccine.&#xD;
&#xD;
          -  Use of any prescribed or non-prescribed drugs, alternative and complementary&#xD;
             medications, except for vitamins, contraceptives, hormone replacement therapy and&#xD;
             occasional acetaminophen (to a maximum of 2 g/day), within 14 days prior to first&#xD;
             injection with ASP0113.&#xD;
&#xD;
          -  Vaccination with killed vaccines (including e.g., influenza and pneumococcal), or&#xD;
             allergy treatment with antigen injections within 15 days prior to day -1.&#xD;
&#xD;
          -  Vaccination with live attenuated vaccines within 30 days prior to day -1.&#xD;
&#xD;
          -  Participated in any interventional clinical study or has been treated with any&#xD;
             investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to&#xD;
             day 1.&#xD;
&#xD;
          -  History of consuming more than 14 units of alcoholic beverages per week within 6&#xD;
             months prior to Screening or has a history of alcoholism or drug/chemical/substance&#xD;
             abuse within past 2 years prior to Screening (Note: 1 unit = 12 ounces of beer, 4&#xD;
             ounces of wine or 1ounce of spirits/hard liquor).&#xD;
&#xD;
          -  Positive test for alcohol or drugs of abuse at Screening or day -1.&#xD;
&#xD;
          -  Significant blood loss, donation of 1 unit (450 mL) or more of blood or receipt of a&#xD;
             transfusion of any blood, blood products or plasma within 90 days of day -1.&#xD;
&#xD;
          -  Contraindication to an intramuscular (IM) injection.&#xD;
&#xD;
          -  Employee of the Astellas Group or contract research organization (CRO) involved.&#xD;
&#xD;
        Exclusion Criteria for Dialysis Patients:&#xD;
&#xD;
          -  Female subject is pregnant at Screening.&#xD;
&#xD;
          -  Any clinically significant history of allergic conditions (including drug allergies,&#xD;
             asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies).&#xD;
&#xD;
          -  Any history or evidence of any unstable, clinically significant cardiovascular,&#xD;
             gastrointestinal, endocrinologic, hematologic, hepatic, metabolic, pulmonary,&#xD;
             neurologic, dermatologic, psychiatric and/or other major disease or malignancy.&#xD;
&#xD;
          -  History of prior organ transplant, including a kidney, unless the transplant was&#xD;
             unsuccessful and the subject is no longer receiving immunosuppressive therapy.&#xD;
&#xD;
          -  History or evidence of autoimmune diseases including systemic lupus erythematosus,&#xD;
             rheumatoid arthritis, scleroderma, psoriasis, psoriatic arthritis and inflammatory&#xD;
             bowel disease or other disease which may require use of an immunosuppressant&#xD;
             medication during the trial.&#xD;
&#xD;
          -  Febrile illness or symptomatic, viral, bacterial (including upper respiratory&#xD;
             infection), or fungal (non-cutaneous) infection within 1 week prior to day-14.&#xD;
&#xD;
          -  Hemoglobin &lt; 9 g/dL, TBil greater than the upper limit of normal (ULN), or an AST or&#xD;
             ALT greater than 2 x the ULN at Screening. In such cases the assessment may be&#xD;
             repeated once.&#xD;
&#xD;
          -  Mean pulse &lt; 40 or &gt; 100 bpm or mean SBP &gt; 180 mmHg; mean DBP &gt; 100 mmHg taken in&#xD;
             triplicate after the subject has been resting in a sitting position for at least 5&#xD;
             minutes at Screening.&#xD;
&#xD;
          -  Positive serology test for HBsAg or HBc (IgM), anti HAV (IgM), anti-HIV-1 or&#xD;
             anti-HIV-2 at Screening.&#xD;
&#xD;
          -  Positive serology test for anti-HCV and a confirmatory positive reflex viral load test&#xD;
             at Screening.&#xD;
&#xD;
          -  Current/active CMV infection as evidenced by positive CMV PCR plasma results at&#xD;
             Screening.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to ASP0113 or any components of the formulation&#xD;
             used, including aminoglycosides as kanamycin is used during the manufacturing of the&#xD;
             vaccine.&#xD;
&#xD;
          -  Use of alternative and complementary medications except for vitamins, within 14 days&#xD;
             prior to first injection with ASP0113.&#xD;
&#xD;
          -  Subject has had use of any immunosuppressive drugs, including but not limited to,&#xD;
             systemic corticosteroids within 14 days or 5 half-lives of initial injection,&#xD;
             whichever is longer. History of topical or inhaled corticosteroid use should be&#xD;
             discussed with the Medical Monitor for evaluation.&#xD;
&#xD;
          -  Use of anticoagulants, including, but not limited to, vitamin K antagonists, heparin&#xD;
             or its derivatives, low molecular weight heparin, factor X inhibitors or thrombin&#xD;
             inhibitors within 5 half-lives of the first ASP0113 injection. Low dose anticoagulants&#xD;
             used for prevention of deep vein thrombosis, prevention of fistula clotting,&#xD;
             prevention of cardiovascular clotting, and heparin for use with dialysis procedure&#xD;
             will be allowed after review and approval from the medical monitor.&#xD;
&#xD;
          -  Vaccination with killed vaccines (including e.g., influenza and pneumococcal), or&#xD;
             allergy treatment with antigen injections between the date of screening and day-1.&#xD;
&#xD;
          -  Vaccination with live attenuated vaccines within 30 days prior to day-1.&#xD;
&#xD;
          -  Participated in any interventional clinical study or treatment with any&#xD;
             investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to&#xD;
             day 1.&#xD;
&#xD;
          -  History of consuming more than 14 units of alcoholic beverages per week within 6&#xD;
             months prior to Screening or has a history of alcoholism or drug/chemical/substance&#xD;
             abuse within past 2 years prior to Screening (Note: 1 unit = 12 ounces of beer, 4&#xD;
             ounces of wine or 1 ounce of spirits/hard liquor).&#xD;
&#xD;
          -  Positive test for alcohol or drugs of abuse (non-prescribed) at Screening or day -1.&#xD;
&#xD;
          -  Significant blood loss, donated 1 unit (450 mL) or more of blood or receipt of a&#xD;
             transfusion of any blood, blood products or plasma within 90 days of day -14.&#xD;
&#xD;
          -  Contraindication to an IM injection.&#xD;
&#xD;
          -  Employee of the Astellas Group or CRO involved in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US10009</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10003</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10001</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10004</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=309</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytomegalovirus</keyword>
  <keyword>ASP0113</keyword>
  <keyword>CMV-seropositive</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>CMV-seronegative</keyword>
  <keyword>Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

